Instead, her doctor prescribed Plavix
. The Plavix
might have helped her leg pain.
FRIDAY, March 16, 2018 (HealthDay News) -- For patients aged older than 65 years with an acute coronary syndrome (ACS) hospitalization, generic clopidogrel is noninferior to Plavix
for the composite of death and recurrent hospitalization for ACS, according to a study published online March 13 in Circulation: Cardiovascular Quality and Outcomes.
The patient was admitted with a diagnosis of dementia from an assisted living facility in a nearby town and was taking two daily medications: Plavix
(history of stroke) and Depakote (history of seizures).
Contract awarded for expression of interest bids for purchase clopidogrel 75 mg tablet, igss code 185, trademark plavix
, required by various medical units of the institute.
Ongoing Consultation Order Viagra, Plavix
, Cialis & more.
Two antiplatelet agents, aspirin and clopidogrel (Plavix
), are commonly given along with the anticoagulant warfarin (Coumadin) to patients with atrial fibrillation who have a heart attack or undergo stent placement.
Comments: Revenues were pounded by patent expiration for Avapro/Avalide (-78%) in March 2012 and Plavix
(-95%) in May 2012.
In a case that sets a new precedent for the pharmaceuticals industry, French competition authorities have fined the Sanofi laboratory 40.6 million for a smear campaign against copies of generic versions of Plavix
, a medicine that had global sales of 2 billion in 2011.
I received conflicting answers from my doctors regarding how long to take Plavix
. Some say "forever," others say "two to three years per the studies." I have an ejection fraction of 50 percent and my labs are good, but I am very bruised.
"Substituting prasugrel (Effient) for clopidogrel (Plavix
) in stented patients on triple therapy may increase the risk of bleeding," according to a study (3/22) published in the Journal of the American College of Cardiology.
The heart drug competes directly with Plavix
, from Bristol-Myers Squibb (NYSE:BMY), but only generated a disappointing $324 million worldwide in 2012.
Healthcare company Sanofi (Euronext:SAN)(NYSE:SNY) and biopharmaceutical company Bristol-Myers Squibb Company (NYSE:BMY) today announced they have restructured their long-term alliance following the loss of exclusivity of Plavix
and Avapro/Avalide in many major markets.